Corporate
News release
TopTOKYO, JAPAN - July 10, 2019 - Terumo Corporation (TSE: 4543) today announced the launch of MISAGO™ RX Self-expanding Peripheral Stent for the use in iliac arteries, in mid-July. The product will be used for the treatment of peripheral artery disease (PAD) in the Japanese market.
Terumo initially introduced MISAGO as the world's first RX self-expanding stent system for the superficial femoral artery (SFA). This time, MISAGO has newly obtained additional market approval for the use in iliac arteries along with the original SFA approval. As such, a hydrophilic coating on the distal tip and the stent sheath has been added to the design, intended for an even smoother access to the lesion. Moreover, further extension of the product is in line for future launch ― a stent system with a longer shaft, designed to access peripheral lesions from the radial artery.
PAD is a disease where cholesterol, fatty deposits and/or calcium known as plaque, narrow or block arteries limiting blood flow to the limbs. The result can cause leg pain, cramping and difficulty walking. More severe symptoms may cause complications such as chronic skin ulceration, gangrene, leg amputation, infection and death.
Stent therapy is currently the gold standard for PAD patients with iliac arterial lesion. Terumo will aim to acquire 25% local market share, as this new additional launch will help Terumo provide wider treatment options for physicians in interventional therapy.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.